Tern Pharmaceuticals (TERN) Soars 630% on CML Treatment Best-in-Class Potential

We recently published 10 Market Stars Behind Millionaire-Making in 2025. Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is one of the top performers.

Terns Pharmaceuticals climbed by 629.64 percent in 2025, primarily boosted by stellar results from the clinical trial of its therapy candidate for chronic myeloid leukemia (CML), which has the potential to become the best-in-class therapy versus other existing treatments.

At the 67^th American Society of Hematology (ASH) Annual Meeting and Exposition early last month, Terns Pharmaceuticals Inc. (NASDAQ:TERN) said that its therapy candidate, TERN-701, recorded a 64 percent improvement in the conditions of 63 enrolled patients with CML after taking the pill for 24 weeks.

Additionally, it saw a 74 percent major molecular response rate at higher doses of 320 mg.

Of the total enrollees, 55 patients remained on treatment, with four dropping out due to disease progression.

Meanwhile, three stopped due to the physician and patient’s decision, while one stopped after experiencing adverse effects.

Following the results, Terns Pharmaceuticals, Inc. (NASDAQ:TERN) successfully raised $747.5 million in fresh funds from the issuance of more than 18.68 million shares to the public. Part of the proceeds will be allocated for the development, manufacturing, preparation, and future commercial launch of TERN-701, while the balance will be used for working capital and other general corporate purposes.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.